{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-012259","form_type":"8-K","ticker":"CATX","cik":"0000728387","company_name":"Perspective Therapeutics, Inc.","filed_at":"2026-01-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:37.598864+00:00","generated_at":"2026-05-16T10:30:47.234095+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"medium","headline":"Perspective Therapeutics updates corporate presentation with pipeline progress and 2026 data expectations","bullets":["Lead programs VMT-α-NET (SSTR2+ NETs), VMT01 (MC1R melanoma), PSV359 (FAP-α) all in Phase 1/2a trials.","Proprietary 212Pb-based radioligand platform and chelator designed for broader use; manufacturing underway.","Phase 1/2 data expected across all three clinical programs in 2026.","Preliminary anti-tumor activity observed for VMT01 at lower dose; well-tolerated safety profile.","VMT-α-NET shows compelling anti-tumor activity and best-in-class safety; potential registration study at current dose."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-012259","json":"https://secwatch.observer/filing/0001193125-26-012259.json","markdown":"https://secwatch.observer/filing/0001193125-26-012259.md","text":"https://secwatch.observer/filing/0001193125-26-012259.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/728387/000119312526012259/0001193125-26-012259-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/728387/000119312526012259/catx-20260114.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T10:30:47.234095+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}